A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE DOSE, 2-WAY CROSSOVER STUDY ASSESSING PHARMACOKINETIC COMPARABILITY OF TWO PF-06881894 PRESENTATIONS, ON-BODY INJECTOR AND PREFILLED SYRINGE, IN HEALTHY PARTICIPANTS
Latest Information Update: 14 Aug 2024
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Neutropenia
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 29 Aug 2022 Status changed from active, no longer recruiting to completed.
- 11 May 2022 Planned End Date changed from 11 Jul 2022 to 7 Jul 2022.
- 11 May 2022 Planned primary completion date changed from 11 Jul 2022 to 7 Jul 2022.